Sun Pharma gets 6 USFDA observations for Mohali facility

New Delhi: Drugmaker, Sun Pharmaceutical Industries Limited, has recently announced that the US Food and Drug Administration (USFDA) has concluded an inspection with 6 observations at the company's Mohali manufacturing facility (Punjab, India).

The USFDA conducted an inspection from August 3, 2022 to August 12, 2022.

"At the conclusion of the inspection, the US FDA issued a Form-483, with 6 observations. The Company is preparing the response to the observations, which will be submitted to USFDA within the stipulated timeline," the company stated in its recent BSE filing.

"The Company is committed to address these observations promptly. The Company remains committed to work closely with the USFDA and continues to enhance its compliance on an ongoing basis," the company informed.

Read also: Sun Pharma, Dr Reddy's Labs and 2 others recall products in US